Lexaria Bioscience Corp. (NASDAQ: LEXX) recently published positive results from an animal study evaluating DehydraTECH(TM) treatment of sildenafil, a phosphodiesterase inhibitor (“PDE5 inhibitor”), as a potential use in the management of erectile. “A clear trend emerged during the study – an overall faster and higher delivery of sildenafil into the bloodstream. During the animal study, it was determined that in as little as four minutes of administration, the DehydraTECH formulation of sildenafil delivered an average of 74% more of the PDE5 inhibitor into the bloodstream than the equivalent strength generic control formulation Within seven minutes, the DehydraTECH-sildenafil formulation achieved an average blood level higher higher than the generic control achieved at any time during the study,” reads a recent article. “The best-known sildenafil product on the market is Viagra(R). The drug is bioavailable orally to around 40%, with the most common complaint from consumers being that it is slow to act.The results of Lexaria’s animal study are a first step towards the development of oral formulations of sildenafil that are faster and more efficient. »
To see the full article, visit https://cnw.fm/KVDQe
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more efficient oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10 times and in some cases with cannabinoids up to 27 times compared to standard formulations of the industry, reduce onset time from one to two hours to minutes and masks unwanted tastes. The technology is also being evaluated for oral antiviral drugs, nonsteroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors, and more. DehydraTECH has also demonstrated the ability to deliver certain drugs more efficiently across the blood-brain barrier. Lexaria operates an in-house licensed research laboratory and holds a strong intellectual property portfolio with 23 granted patents and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTICE TO INVESTORS: The latest news and updates regarding LEXX can be found in the company’s newsroom at https://cnw.fm/LEXX
CannabisNewsWire (CNW) is a news service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize company news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communications solutions. As a multi-faceted financial news and content distribution company with an extensive team of reporters and editors, CNW is uniquely positioned to better serve private and public companies seeking to reach a wide audience of investors. , consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 major syndication outlets across the country. By reducing the information overload in today’s marketplace, CNW provides its clients with unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS alerts from CannabisNewsWire, text “CANNABIS” to 21000 (US cell phones only)
For more information, please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our editor
CannabisNewsWire is part of the InvestorBrandNetwork.